Galapagos (Nasdaq: GLPG) to Ring The Nasdaq Stock Market Opening Bell
May 14 2015 - 6:00AM
What:
Galapagos (Nasdaq:GLPG) (Euronext:GLPG) is a clinical-stage
European biotechnology company specialized in the discovery and
development of small molecule medicines with novel modes of
action. Galapagos has just reported positive Phase 2B
research results with filgotinib, a new oral medicine for
rheumatoid arthritis which is partnered with AbbVie.
Galapagos will visit the Nasdaq MarketSite in Times Square in
celebration of its IPO on The Nasdaq Stock Market to raise funds
for research on its remaining novel mode-of-action medicine
programs.
In honor of the occasion, Onno van de Stolpe, Chief
Executive Officer will ring the Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway –
Broadcast Studio
When:
Thursday, May 14, 2015 – 9:15 a.m. to 9:30 a.m.
ET
Galapagos Media Contact:
Elizabeth Goodwin
+31 622 916 240
Elizabeth.goodwin@glpg.com
ir@glpg.com
Nasdaq MarketSite:
Christine Barna
(646) 441-5310
Christine.Barna@nasdaq.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies please visit
our Facebook page at:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram
Page:
http://instagram.com/nasdaq
For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr
Page:
http://nasdaq.tumblr.com/
Webcast:
A webcast of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Open, please
go to http://www.nasdaq.com/reference/marketsite_events.stm and
click on the market open of your choice.
About Galapagos (Euronext: GLPG,
Nasdaq: GLPG):
Galapagos is a clinical-stage biotechnology company specialized
in the discovery and development of small molecule medicines with
novel modes of action, with a pipeline comprising three Phase 2
programs, two Phase 1 trials, five pre-clinical studies, and 25
discovery small-molecule and antibody programs in cystic fibrosis,
inflammation, and other indications. In the field of inflammation,
AbbVie and Galapagos signed a collaboration agreement for the
development and commercialization of filgotinib. Filgotinib is an
orally-available, selective inhibitor of JAK1 for the treatment of
rheumatoid arthritis and potentially other inflammatory diseases,
currently in Phase 2B studies in RA and in Phase 2 in Crohn’s
disease. Galapagos reported good activity and a favorable safety
profile at 12 weeks in both the DARWIN 1 and 2 trials in RA. AbbVie
and Galapagos also signed a collaboration agreement in cystic
fibrosis to develop and commercialize molecules that address
mutations in the CFTR gene. Potentiator GLPG1837 is currently in a
Phase 1 trial, and corrector GLPG2222 is at the pre-clinical
candidate stage. GLPG1205, a first-in-class inhibitor of GPR84 and
fully-owned by Galapagos, is currently being tested in a Phase 2
proof-of-concept trial in ulcerative colitis patients. GLPG1690, a
fully proprietary, first-in-class inhibitor of autotaxin, has shown
favorable safety in a Phase 1 trial and is expected to enter Phase
2 in idiopathic pulmonary fibrosis. The Galapagos Group, including
fee-for-service subsidiary Fidelta, has approximately 400
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. Further
information at: www.glpg.com
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing,
exchange technology, listing, information and public company
services across six continents. Through its diverse portfolio of
solutions, Nasdaq enables customers to plan, optimize and execute
their business vision with confidence, using proven technologies
that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 70
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to more than 3,500 listed companies
with a market value of approximately $9.5 trillion and more than
10,000 corporate clients. To learn more, visit: nasdaq.com/ambition
or business.nasdaq.com.
-NDAQA-
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024